Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

May 15, 2024

https://www.globenewswire.com/news-release/2024/05/15/2882430/0/en/Abstract-on-Phase-2-Study-with-IMUNON-s-IMNN-001-Plus-Bevacizumab-Accepted-for-Presentation-at-the-American-Society-of-Clinical-Oncology-Annual-Meeting.html

LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago from May 31st to June 4th.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.